TGFb is a potent driver of cancer immune suppression, potentially linking Spp1+ macrophages with the inhibition of adaptive immunity.[12] Different therapeutic strategies have been proposed to inhibit SPP1, including the use of monoclonal antibodies, siRNA, aptamers, and small molecule inhibitors.[13, 14] Despite these proposed approaches, no strategy currently exists to effectively antagonize Spp1 in TAM. Here, SPP1 is linked to cancer.